Browsing by Subject "BRAF inhibitors"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Open Access
    Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulation
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2024) Wang, Qiuhan; Hao, Fengyun; Ning, Liang; Sun, Chong
    Pseudopodium-enriched atypical kinase 1 (PEAK1) has been demonstrated to be upregulated in human malignancies and cells. Enhanced PEAK1 expression facilitates tumor cell survival and chemoresistance. However, the role of PEAK1 inhibition to anaplastic thyroid carcinoma cell (ATC) and vemurafenib resistance is still unknown. Here, we observed that targeting PEAK1 inhibited cell viability and colony formation, but not cell apoptosis in both of the 8505C and Hth74 cells in vitro. Targeting PEAK1 sensitized 8505C and Hth74 cells to Vemurafenib by inducing cell apoptosis, and thereby decreasing cell viability. Mechanistically, Vemurafenib treatment upregulated PEAK1 expression. Combined PEAK1 depletion and Vemurafenib treatment upregulated Bim expression. Targeting PEAK1 sensitized Vemurafenib-induced apoptosis by upregulating Bim. In conclusion, Vemurafenib resistance in ATC cells harboring BRAFV600E is associated with PEAK1 activation, resulting in the inhibition of pro-apoptotic Bim protein. Therefore, targeting PEAK1 may be an effective strategy to sensitize ATC harboring BRAFV600E to Vemurafenib.